The present invention is directed to novel inhibitors of the BACE1 enzyme. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders for which the reduction of Aβ deposits is beneficial such as Alzheimers disease.La présente invention concerne de nouveaux inhibiteurs de lenzyme BACE1. Des aspects séparés de linvention concernent des compositions pharmaceutiques comprenant lesdits composés et des utilisations des composés pour traiter des troubles pour lesquels la réduction de dépôts de Aβ est bénéfique, tels que la maladie dAlzheimer.